Literature DB >> 21422636

Cholesterol crystal embolization (CCE): Improvement of renal function with high-dose corticosteroid treatment.

Madhav Desai1, R Ram, Aruna Prayaga, K V Dakshinamurty.   

Abstract

Cholesterol crystal embolization (CCE) is an important and often under-diagnosed cause of renal insufficiency in patients with atherosclerosis. So far, only statins are the mainstay of therapy and the role of corticosteroids is controversial. We describe a 57-year-old gentleman who presented with accelerated hypertension and renal failure three months after coronary angiogram. Renal biopsy showed cholesterol clefts in the arteriole. Initially, management with anti-hypertensives alone (already receiving statins since angiogram) was unsuccessful. A trial of high-dose corticosteroids resulted in an improvement of the general condition in the next two days, and the serum creatinine reduced gradually to 1.6 mg/dL over the next one month. In conclusion, high-dose corticosteroids are useful in the treatment of CCE associated renal failure, especially in cases with no spontaneous recovery of function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422636

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  4 in total

1.  Ileus caused by cholesterol crystal embolization: A case report.

Authors:  Shunjiro Azuma; Maiko Ikenouchi; Takuji Akamatsu; Takeshi Seta; Shunji Urai; Yoshito Uenoyama; Yukitaka Yamashita
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

2.  Favorable outcome in atheroembolic renal disease with pulse steroid therapy.

Authors:  A Sharma; R Hada; R K Agrawal; A Baral
Journal:  Indian J Nephrol       Date:  2012-11

Review 3.  Cholesterol Crystal Embolism and Chronic Kidney Disease.

Authors:  Xuezhu Li; George Bayliss; Shougang Zhuang
Journal:  Int J Mol Sci       Date:  2017-05-24       Impact factor: 5.923

4.  Idiopathic cholesterol crystal embolism with atheroembolic renal disease and blue toes syndrome: A case report.

Authors:  De-Jin Cheng; Lin Li; Xiang-Yue Zheng; Shui-Fu Tang
Journal:  World J Clin Cases       Date:  2022-09-06       Impact factor: 1.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.